132 completed, 123 recruiting, 72 unknown, 71 active not recruiting. 253 Phase 2, 177 Phase 1, 54 Not applicable, 26 Phase 3, 17 Early Phase 1.
Follow this condition Literature Review of Head and Neck Squamous Cell Carcinoma trials Research Report on Head and Neck Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma 64Cu-DOTA-ECL1i - Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 2 | Recruiting | Washington University School of Medicine | 90 | 2026-10-31 | 2026-10-07 |
| A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. LNTH-2403 - Imaging, Colorectal Cancer | Phase 1 | Not yet recruiting | Radiopharm Theranostics, Ltd | 16 | 2026-10-30 | 2026-08-12 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-10-26 | 2026-10-21 |
| MTX-531-001 Phase 1 Study in Advanced Solid Tumors MTX-531 - Solid Tumors (Phase 1), HNSCC | Phase 1 | Not yet recruiting | MEKanistic Therapeutics, Inc. | 71 | 2026-10-20 | 2026-10-15 |
| Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer Multispectral Optoacoustic Tomography, Temperature Measurement - Head and Neck Squamous Cell Carcinoma | Not applicable | Suspended | University of Oklahoma | 100 | 2026-10-01 | 2026-08-18 |
| Hypofractionated Radiotherapy in Older Adults With Head and Neck Squamous Cell Carcinoma Hypofractionated Radiotherapy, Normofractionated Radiotherapy - Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck | Not applicable | Not yet recruiting | Assiut University | 60 | 2026-10-01 | 2026-09-29 |
| Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | caohaotian | 300 | 2026-10-01 | 2026-09-18 |
| Indocyanine Green With Near Infrared Imaging for Intraoperative Visualization of Head and Neck Squamous Cell Carcinoma Indocyanine green, Near-infrared fluorescence imaging - Head and Neck Squamous Cell Carcinoma | Recruiting | Washington University School of Medicine | 25 | 2026-09-30 | 2026-10-09 | |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-09-30 | 2026-08-13 |
| A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors ABBV-253 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | AbbVie | 130 | 2026-09-14 | 2026-10-16 |
| A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | AbbVie | 150 | 2026-09-01 | 2026-10-16 |
| A Study of IOV-5001 in Adults With Advanced Solid Tumors IOV-5001 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Iovance Biotherapeutics, Inc. | 106 | 2026-09-01 | 2026-09-15 |
| Blood Biomarkers Based Screening for HPV-driven OPC HPV16-E6 serology and HPV ctDNA - Head and Neck Squamous Cell Carcinoma, Anal Cancer | Not applicable | Not yet recruiting | UNICANCER | 10000 | 2026-09-01 | 2026-05-26 |
| Thermotherapy for Head and Neck Cancer Patients Thermotherapy, Radiotherapy, Concurrent chemoradiation - Head and Neck Cancer, Oropharyngeal Carcinoma | Phase 1 | Recruiting | Erasmus Medical Center | 30 | 2026-09-01 | 2026-09-02 |
| A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease - Head and Neck Cancer, Head and Neck Squamous Cell Cancer | Phase 2 | Not yet recruiting | University of Maryland, Baltimore | 132 | 2026-09-01 | 2026-08-14 |
| Online Sharing for Head & Neck Cancer Support Social Sharing-Based Mobile Application, Usual Care with Psycho-educational Manual - Head and Neck Squamous Cell Carcinoma | Not applicable | Recruiting | West China Hospital | 120 | 2026-08-28 | 2026-09-02 |
| SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC SYS6010, Investigator's Choice of monotherapy - Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 340 | 2026-08-15 | 2026-08-11 |
| MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma MRG003 (Becotatug vedotin) and Toripalimab, Toripalimab - Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Dongguan People's Hospital | 65 | 2026-08-10 | 2026-08-05 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 454 | 2026-07-31 | 2026-08-17 |
| A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Becotatug Vedotin, Becotatug Vedotin Combined with Penpulimab, Becotatug Vedotin Combined with Ivonescimab - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | West China Hospital | 90 | 2026-07-20 | 2026-09-11 |
Showing 20 of 504. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (504) · Head and Neck Neoplasms (110) · Carcinoma, Non-Small-Cell Lung (83) · Melanoma (54) · Colorectal Neoplasms (46) · Triple Negative Breast Neoplasms (36) · Breast Neoplasms (30) · Carcinoma, Renal Cell (27) · Neoplasm Metastasis (27) · Stomach Neoplasms (27) · Uterine Cervical Neoplasms (27) · Carcinoma, Squamous Cell (24) · Neoplasms (24) · Mouth Neoplasms (22) · Oropharyngeal Neoplasms (22)
Neoplasms by Histologic Type (504) · Neoplasms by Site (504) · Neoplasms, Glandular and Epithelial (504) · Carcinoma (488) · Carcinoma, Squamous Cell (480) · Neoplasms (480) · Head and Neck Neoplasms (394) · Respiratory Tract Diseases (120) · Respiratory Tract Neoplasms (117) · Skin Diseases (99) · Skin and Connective Tissue Diseases (99) · Thoracic Neoplasms (98) · Lung Diseases (97) · Digestive System Diseases (88) · Digestive System Neoplasms (87)
pembrolizumab (84) · Cisplatin (48) · Cetuximab (34) · Carboplatin (26) · Radiotherapy (25) · Docetaxel (20) · Paclitaxel (19) · Fluorouracil (17) · Nivolumab (16) · Radiotherapy, Intensity-Modulated (13) · Magnetic Resonance Spectroscopy (12) · 130-nm albumin-bound paclitaxel (10) · Drug Therapy (10) · tislelizumab (9) · toripalimab (9)
West China Hospital (12) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (11) · National Cancer Institute (NCI) (10) · Washington University School of Medicine (8) · M.D. Anderson Cancer Center (7) · Sichuan Baili Pharmaceutical Co., Ltd. (7) · Memorial Sloan Kettering Cancer Center (6) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (6) · University Health Network, Toronto (6) · Providence Health & Services (5) · Roswell Park Cancer Institute (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · AbbVie (4) · AstraZeneca (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (4)
United States (241) · China (111) · France (39) · Spain (37) · Australia (30) · United Kingdom (29) · Canada (28) · Italy (26) · South Korea (26) · Taiwan (25) · Germany (20) · Netherlands (16) · Belgium (15) · Singapore (13) · Japan (12)
Yuankai Shi, MD (7) · Douglas R Adkins, M.D. (4) · Anurag K Singh (3) · Eben Rosenthal, MD (3) · Lara Dunn, MD (3) · Mikhail Samsonov (3) · Ari Rosenberg, MD (2) · Aron Popovtzer, MD (2) · Barbara Burtness, MD (2) · Brendan D. Curti, MD (2) · Chaosu Hu (2)
PMID 25979390, PMID 40511820, PMID 16763816, PMID 16824985, PMID 17448882, PMID 17869020, PMID 22180229, PMID 24879333, PMID 25527417, PMID 25564570, PMID 25728526, PMID 27345843, PMID 27663515, PMID 28131786, PMID 28249612, PMID 28328302, PMID 28864403, PMID 28911070, PMID 29203590, PMID 29472484, PMID 29710393, PMID 30045932, PMID 30350310, PMID 30642290, PMID 31175091, PMID 31214178, PMID 31236579, PMID 31395089, PMID 31796519, PMID 31873950, PMID 31892671, PMID 33243986, PMID 33300372, PMID 33336372, PMID 33492986, PMID 33605440, PMID 33613701, PMID 3365707, PMID 33684370, PMID 33816283, PMID 33963014, PMID 33989559, PMID 34900741, PMID 35065058, PMID 35091445, PMID 35098345, PMID 35101941, PMID 35276694, PMID 35362047, PMID 35395276
2023 (7), 2018 (3), 2019 (3), P30CA014089 (3), 2014 (2), P30CA012197 (2), P30CA015704 (2), P30CA138292 (2), U10CA180820 (2), U10CA180868 (2), UM1CA186691 (2), 2008 (1), 2017 (1), 2025 (1), K07CA215546 (1)